Can you provide the average price target for HUMACYTE INC stock?
13 analysts have analysed HUMA and the average price target is 8.01 USD. This implies a price increase of 1251.02% is expected in the next year compared to the current price of 0.5932.
HUMACYTE INC (HUMA) Forecast, Price Target & Analyst Ratings
NASDAQ:HUMA • US44486Q1031
Current stock price
0.5932 USD
-0.01 (-2.23%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HUMACYTE INC (HUMA).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.12
- Revenue Estimate
- 4.016M
Price Target Details & History
Consensus Price Target and Range
Mean target
$8.01
Upside
+ 1,251.02%
From current price of $0.59 to mean target of $8.01, Based on 13 analyst forecasts
Low
$3.03
Median
$3.57
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
13 Wall Street analysts provided a forecast for the next 12 months for HUMA. The average price target is 8.01 USD. This implies a price increase of 1251.02% is expected in the next year compared to the current price of 0.5932.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.54%
HUMA was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about HUMA.
In the previous month the buy percentage consensus was at a similar level.
HUMA was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-31 | Benchmark | Downgrade | Buy -> Speculative Buy |
| 2026-03-30 | TD Cowen | Maintains | Buy -> Buy |
| 2026-03-30 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2026-03-27 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-03-27 | BTIG | Maintains | Buy -> Buy |
| 2026-03-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-03-17 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-02-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-02-09 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-02-09 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-21 | Benchmark | Maintains | Buy -> Buy |
| 2026-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-05 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-21 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-13 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-13 | Benchmark | Maintains | Buy -> Buy |
| 2025-11-12 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-10 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-13 | BTIG | Maintains | Buy -> Buy |
| 2025-10-06 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-30 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-15 | D. Boral Capital | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.12
- Revenue Estimate
- 4.016M
- Revenue Q2Q
- 676.79%
- EPS Q2Q
- -143.71%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
HUMA is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.12 USD and the consensus revenue estimate is 4.02M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.49M -75.93% | 1.26M -15.44% | 1.57M 24.60% | 58.283K -100.00% | 218.576K | 2.882M | 23.951M 731.05% | 93.532M 290.51% | 346.79M 270.77% | 584.41M 68.52% | 975.46M 66.91% | 1.886B 93.34% | 2.585B 37.06% | 3.094B 19.69% | |
| EBITDA YoY % growth | -56.25M 28.74% | -72.96M -29.71% | -76.37M -4.67% | -98.634M -20.90% | -83.232M -15.69% | -60.486M 43.37% | 714K 101.18% | 12.75M 1,685.71% | 68.952M 440.80% | 130.25M 88.90% | 212.47M 63.12% | 308.04M 44.98% | N/A | N/A | |
| EBIT YoY % growth | -64.6M 24.61% | -81.2M -25.70% | -84.58M -4.16% | -100.904M -18.29% | -118.406M -13.95% | -102.185M 10.36% | -85.698M 16.14% | -65.086M 24.05% | 156.49M 340.43% | 351.9M 124.87% | 681.82M 93.75% | 1.314B 92.72% | 1.838B 39.88% | 2.326B 26.55% | |
| Operating Margin | -4,335.57% | -6,444.44% | -5,387.26% | -173,128.65% | -54,171.38% | -3,545.64% | -357.80% | -69.59% | 45.13% | 60.21% | 69.90% | 69.67% | 71.10% | 75.18% | |
| EPS YoY % growth | N/A | -0.51 | -0.13 74.51% | -1.08 -723.08% | -1.38 -17.76% | -0.31 84.13% | -0.46 -127.80% | -0.34 26.12% | 2.10 724.24% | 3.81 81.55% | 7.20 88.77% | 9.69 34.56% | 12.53 29.26% | 12.82 2.36% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 -143.71% | -0.11 52.19% | -0.10 4.95% | -0.09 29.38% | -0.04 66.67% | -0.02 82.22% | 0.01 109.76% | 0.04 144.44% |
| Revenue Q2Q % growth | 4.016M 676.79% | 6.036M 1,905.32% | 8.04M 967.73% | 10.116M 2,052.34% | 25.704M 540.04% | 34.272M 467.79% | 43.35M 439.18% | 52.938M 423.31% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.063M 9.15% | -20.196M 32.06% | -18.768M 23.05% | -17.544M 24.49% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
132.12%
EPS Next 5 Year
107.00%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
393.69%
Revenue Next 5 Year
220.56%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
28.21%
EBIT Next 5 Year
25.39%
HUMACYTE INC / HUMA Forecast FAQ
What is the next earnings date for HUMA stock?
HUMACYTE INC (HUMA) will report earnings on 2026-05-11.
What are the consensus estimates for HUMA stock next earnings?
The consensus EPS estimate for the next earnings of HUMACYTE INC (HUMA) is -0.12 USD and the consensus revenue estimate is 4.02M USD.
What is the consensus rating for HUMA stock?
The consensus rating for HUMACYTE INC (HUMA) is 81.5385 / 100 . This indicates that analysts generally have a positive outlook on the stock.